Impact of the azoximer bromide concomitant therapy on outcomes in patients with soft tissue sarcoma

Autor: Dilorom Khamidovna Latipova, Svetlana Protsenko, Irina Alexandrovna Baldueva, Natalya Shendaleva, Anton Zozulya, Anna Semenova, Gulfiya Midhatovna Teletaeva, Tatyana Nekhaeva, Aleksei Viktorovich Novik, Tatiana Semiglazova
Rok vydání: 2021
Předmět:
Zdroj: Journal of Clinical Oncology. 39:e23534-e23534
ISSN: 1527-7755
0732-183X
DOI: 10.1200/jco.2021.39.15_suppl.e23534
Popis: e23534 Background: Immunomodulators are used in the management of patients with soft tissue sarcoma, (STS). However, the precise mechanism behind their benefits in anticancer therapy effects have yet to be determined. We assessed the impact of the immunomodulator azoximer bromide (AB) as a prognostic factor for survival when used concomitant with standard therapy in patients with STS. Methods: We reviewed medical history and disease outcomes in STS patients attending the Petrov National Medical Research Centre of Oncology (St Petersburg, Russia). Data were collected per protocol on treatments and patient outcomes. A Cox proportional-hazards model for time-to-progression (TTP) was constructed in SPSS v19. Known prognostic factors (TNM stage and substage, sex, age, therapy by type, and by immunologic action, as well as treatment modality), setting and AB therapy extracted from patient records were included in the model. The model employed a ‘step-forward’ method with AB therapy identified as the ‘unknown’ variable. Results: Complete patient records were available on 243 clinic attendees (from 2010 to 2020), 25 had received treatment with AB. The median follow-up was 20.9 months. Patients received single- and multi-agent chemotherapy, vaccines, cytokines, radiation therapy and/or surgery in the adjuvant or metastatic setting. Significant factors in the TTP model were current therapy type (Hazards ratios: 0.59 for surgery, 0.533 per added method for complex therapy and HR 1.689 for single-agent chemotherapy), previous systemic chemotherapy (HR: 1.451) and AB therapy (HR 0.547). Conclusions: Use of AB with standard therapy in STS emerged as an independent favorable prognostic factor. Appropriately controlled, well-designed prospective trials are needed to investigate this finding further. [Table: see text]
Databáze: OpenAIRE
Externí odkaz: